Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause
of cancer-related death and its incidence is increasing globally. Around 50% of patients …

Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1),
a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1 , 2 , 3 , 4 – 5 . Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been …

… Pinato reports grant funding in support of clinical trials from Merck Sharpe & Dohme and …
Dr Pinato is supported by grant funding from the National Institute for Health Research and …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). …

Background & Aims Overall survival (OS) is a composite clinical endpoint in hepatocellular
carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating …

… David J. Pinato acknowledges infrastructural and grant support from the NIHR Imperial
Experimental Cancer Medicine Centre and the Imperial College BRC. … Pinato and …

Background: There is increasing evidence that the presence of an ongoing systemic
inflammatory response is a stage-independent predictor of poor outcome in patients with cancer. …

In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality
was 33.6% and predicted by male gender, age ≥65, and comorbidity burden. Delivery of …